All In Biotech

NDA 017469 · Sandoz

Omnipred

Prednisolone Acetate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1973

Jul 10, 1973

Approved uses

2

Original approval plus efficacy supplements

Registered trials

2,078

579 Phase 3, 236 recruiting

FAERS reports

8,432

3,975 serious, 454 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 23, 2026.

INDICATIONS AND USAGE: Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 29, 1995 Supplement 18 · Efficacy
  • Jul 10, 1973 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • OMNIPRED · PREDNISOLONE ACETATE 1% · SUSPENSION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Prednisolone" as an intervention, any sponsor and status, largest first.

All 2,078 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure1,251
  • drug ineffective768
  • recalled product administered763
  • no adverse event641
  • off label use537
  • eye pain473
  • eye irritation314
  • vision blurred282
  • fatigue255
  • headache239
  • diarrhoea220
  • condition aggravated209

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200531
200635
200770
2008130
200951
201070
201170
2012160
201393
2014125
2015243
2016483
2017280
2018404
2019471
20201,633
2021432
2022505
2023588
2024628
2025663
20261,250

Recalls

1 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,678 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.